对慢性异常性腹患者的诊断和管理的建议:基于修改后的Delphi方法的比利时多学科专家讨论
T Vanuytsel1, J Arts2, V Casneuf3
1University Hospitals Leuven, Leuven, Belgium.
Acta gastro-enterologica Belgica
|June 12, 2025
概括
专家们在诊断慢性异常性腹 (CID) 上达成共识,但由于证据有限,在治疗策略上存在分歧. 这项研究突出了管理CID的当前临床实践.
科学领域:
- 胃肠病学 胃肠病学
- 临床诊断 临床诊断 临床诊断
- 基于证据的医学基于证据的医学.
背景情况:
- 慢性腹是一种常见的胃肠道疾病,具有广泛的差异诊断.
- 一部分患者呈现慢性异常性腹 (CID),没有确定潜在原因.
- 建立一个清晰的CID诊断途径对于有效的患者管理至关重要.
研究的目的:
- 开发一种基于共识的慢性腹诊断策略,优化诊断产量,尽量减少侵入性手术.
- 为了在慢性异常性腹患者的最佳治疗选择上达成专家协议.
- 描述当前的临床实践,并确定CID管理的进一步研究领域.
主要方法:
- 使用德尔菲模型,促进专家就慢性腹的诊断和治疗方法达成共识.
- 来自不同背景的专家参与了建立共识的过程.
- 该方法专注于最大限度地提高诊断准确度,同时尽量减少调查的侵入性.
主要成果:
- 在慢性异常性腹 (CID) 的基本诊断测试方面达成了共识.
- 专家们注意到,在CID的首选治疗策略和选择方面,专家之间存在很大的分歧.
- 缺乏针对特定治疗方法的强有力的科学证据,通常是从腹刺激性肠综合征 (IBS-D) 推断出来的,是治疗分歧的基础.
结论:
- 德尔菲过程有效地激发了讨论,并概述了治疗慢性异常性腹 (CID) 的当前临床实践.
- 虽然存在诊断共识,但由于证据不足,CID的治疗策略仍然不尽相同.
- 需要进一步的研究,以建立基于证据的慢性异常性腹治疗指南.
相关概念视频
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
323
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
323
01:17Drugs for Treatment of Diarrhea-Predominant IBS
152
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
152
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
178
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
178
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
146
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
146
01:29Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118
01:29Chronic Pancreatitis II: Collaborative Care
70
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
70